Impact of diaphragm weakness in ICU patients

Incidence and Impact of ICU-acquired Diaphragm Weakness

Assistance Publique - Hôpitaux de Paris · NCT06420999

This study looks at how weak diaphragm muscles affect recovery in ICU patients after they leave the hospital to see if it impacts their breathing and overall health in the following months.

Quick facts

Study typeObservational
Enrollment194 (estimated)
Ages18 Years and up
SexAll
SponsorAssistance Publique - Hôpitaux de Paris (other)
Locations1 site (Paris)
Trial IDNCT06420999 on ClinicalTrials.gov

What this trial studies

This observational study evaluates the incidence and prognostic impact of diaphragm dysfunction in patients discharged from the ICU. It involves assessing diaphragmatic function using ultrasound within 24 hours after weaning from ventilatory support and on the day of ICU discharge. The study aims to correlate diaphragmatic activity with patient outcomes, specifically looking at the relationship between diaphragmatic dysfunction and prognosis within 90 days post-discharge. Dyspnea will also be measured to provide a comprehensive evaluation of respiratory muscle function.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 years and older who have received respiratory support for at least 48 hours and are being weaned from that support.

Not a fit: Patients with known pre-existing diaphragmatic dysfunction or those who are non-communicative may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved monitoring and management strategies for ICU patients, potentially reducing readmission rates and improving long-term outcomes.

How similar studies have performed: While the specific focus on ICU-acquired diaphragm weakness is novel, related studies have shown that assessing respiratory muscle function can provide valuable prognostic information.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years
2. Invasive or non-invasive respiratory support (ventilation, high-flow oxygen therapy, whatever the reason) for at least 48 hours.
3. Weaning from respiratory support (invasive or not) within the last 24 hours.
4. Patient (or trusted person/relative) informed and not opposed to the study.

Exclusion Criteria:

1. Known pre-existing diaphragmatic dysfunction (phrenic lesion, neuromuscular disease, etc.)
2. Patients with tracheostomy
3. Non-communicating patients
4. Patients deprived of liberty by court or administrative order, or under legal protection (guardianship, curators).

Where this trial is running

Paris

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Diaphragm Dysfunction, ICU, diaphragmatic activity, Respiratory support

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.